Grant of Options and Restricted Stock Units

MXCT 10.18.2024

Full Press ReleaseSEC FilingsOur MXCT Tweets

About Gravity Analytica

Recent News

  • 01.22.2025 - Holding(s) in Company

Recent Filings

    RNS Number : 7726I
    MaxCyte, Inc.
    18 October 2024

    MaxCyte, Inc.

    ("MaxCyte" or the "Company")

    Grant of Options and Restricted Stock Units

    ROCKVILLE, MD,October 18, 2024:MaxCyte Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development, and commercialization of next-generation cell therapeutics and to support innovative, cell-based research, announces that on14 October 2024,Cynthia Collins, a non-executive director, has been granted total of 97,698 options ("Option Grant") in respect of common stock in the Company ("Common Stock"), and 51,679 restricted stock units ("RSU"s), which were agreed in September pursuant to Cynthia's appointment.

    The Option Grant vests over three (3) years, with the initial vesting of 1/3rdof the total after twelve (12) months, and the remainder vesting monthly over the following 24 months. The Option Grant have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price ofMaxCyte'sstock on14 October 2024, of$3.87on theUnited States Nasdaq Stock Exchange.

    The RSUs vest at the end of twelve (12) months after date of grant. (1 year cliff until fully vested).

    AboutMaxCyte

    AtMaxCyte, we pursue cell engineering excellence to maximize the potential of cells to improve patients' lives. We have spent more than 20 years honing our expertise by building best-in-class platforms, perfecting the art of the transfection workflow, and venturing beyond today's processes to innovate tomorrow's solutions.Our ExPERTTM platform, which is based on our Flow Electroporation®technology, has been designed to support the rapidly expanding cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. The ExPERT family of products includes: four instruments, the ATxTM, STxTM,GTxTM and VLx TM; a portfolio of proprietary related processing assemblies or disposables; and software protocols, all supported by a robust worldwide intellectual property portfolio. Byproviding our partners with the right technology, as well as technical and regulatory support, we aim to guide them on their journey to transform human health.Learn more atmaxcyte.comand follow us onTwitterandLinkedIn.

    MaxCyte Contacts:

    US IR Adviser

    Gilmartin Group

    David Deuchler, CFA

    +1 415-937-5400

    ir@maxcyte.com

    Nominated Adviser and Joint Corporate Broker

    Panmure Liberum

    Emma Earl/Freddy Crossley

    Corporate Broking

    Rupert Dearden

    +44 (0)20 7886 2500

    UKIR Adviser

    ICR Consilium

    Mary-Jane Elliott

    Chris Welsh

    +44 (0)203 709 5700

    maxcyte@consilium-comms.com

    NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

    1

    Details of the person discharging managerial responsibilities / person closely associated

    a)

    Name

    Cynthia Collins

    2

    Reason for the notification

    a)

    Position/status

    Non-Executive Director

    b)

    Initial notification /Amendment

    Initial notification

    3

    Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

    a)

    Name

    MaxCyte, Inc.

    b)

    LEI

    54930053YHXULRFCU991

    4

    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

    a)

    Description of the financial instrument, type of instrument

    Common Stock of$0.01each

    Identification code

    US57777K1060

    b)

    Nature of the transaction

    Grant ofoptions of common stock

    c)

    Price(s) and volume(s)

    97,698 Options at an exercise price of$3.87

    d)

    Aggregated information

    - Aggregated volume

    N/A

    - Price

    N/A

    e)

    Date of the transaction

    14 October 2024

    f)

    Place of the transaction

    US Stock Exchange, Nasdaq

    1

    Details of the person discharging managerial responsibilities / person closely associated

    a)

    Name

    Cynthia Collins

    2

    Reason for the notification

    a)

    Position/status

    Non-Executive Director

    b)

    Initial notification /Amendment

    Initial notification

    3

    Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

    a)

    Name

    MaxCyte, Inc.

    b)

    LEI

    54930053YHXULRFCU991

    4

    Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

    a)

    Description of the financial instrument, type of instrument

    Grant ofrestricted stock units

    Identification code

    US57777K1060

    b)

    Nature of the transaction

    Grant ofoptions of restricted stock units

    c)

    Price(s) and volume(s)

    51,679 restricted stock units, price N/A

    d)

    Aggregated information

    - Aggregated volume

    N/A

    - Price

    N/A

    e)

    Date of the transaction

    14 October 2024

    f)

    Place of the transaction

    US Stock Exchange, Nasdaq

    This information is provided by RNS, the news service of theLondon Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in theUnited Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contactrns@lseg.comor visitwww.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and theLondon Stock Exchangeuse the personal data you provide us, please see ourPrivacy Policy.
    END
    DSHGIBDGBDBDGSI
    Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com